agendia.com Open in urlscan Pro
2a06:98c1:3120::3  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
Toggle Navigation
 * Our Tests
   * Overview
   * MammaPrint
   * BluePrint
 * Clinical Science
   * Ongoing Trials
     * FLEX
     * I-SPY2
   * Landmark Trials
     * MINDACT
     * STO-3
     * NBRST
     * NSABP B-42
     * IMPACt
   * Publications & Abstracts
   * Events
 * Resources
   * Resources
   * Order A Test
 * About Us
   * Our Story
   * Our Team
   * News
   * Careers
   * Funding Requests
 * For Patients
   * For Patients
   * Financial Support
 * For Investors
 * Contact Us

CLIENT LOGIN



Homekevin2022-04-21T07:55:47-07:00

QUICK RESULTS


LAY OUT A TREATMENT PLAN AS EARLY AS THE FIRST PATIENT MEETING.


AGENDIA PROVIDES YOU WITH ACTIONABLE INSIGHTS THROUGHOUT YOUR PATIENT’S BREAST
CANCER JOURNEY.

QUICK RESULTS


LAY OUT A TREATMENT PLAN AS EARLY AS THE FIRST PATIENT MEETING.


AGENDIA PROVIDES YOU WITH ACTIONABLE INSIGHTS THROUGHOUT YOUR PATIENT’S BREAST
CANCER JOURNEY.

 

Learn the likelihood of a patient’s breast cancer recurring.

A RISK OF RECURRENCE TEST



 

Determine the underlying genomics driving the growth of a tumor.

A MOLECULAR SUBTYPING TEST


FOR BETTER OUTCOMES


A MORE COMPLETE UNDERSTANDING OF EACH PATIENT’S BREAST CANCER.

Agendia’s genomic testing platforms help you match each patient to the right
treatment at the right time to help minimize under- and over-treatment, and
improve their quality of life.

Order A Test


FOR PROVEN RESULTS


TRUSTED BY LEADING PHYSICIANS AND INSTITUTIONS AROUND THE WORLD

Landmark Studies

Data on the validation and utility of MammaPrint and BluePrint for patients with
early stage breast cancer.


Review our data

Latest News

The most recent data and news from Agendia to keep you up-to-date on how our
tests can support you and your patients.


Read more here

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series
illustrating people touched by breast cancer.


View the portrait series


ARE YOU A BREAST CANCER PATIENT?

Learn more about how genomic testing can improve your path to recovery.

VISIT OUR PATIENT ADVOCACY SITE


ARE YOU A BREAST CANCER PATIENT?

Learn more about how genomic testing can improve your path to recovery.

VISIT OUR PATIENT ADVOCACY SITE






Quick Links



Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal



Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact



For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

© 2022 Agendia. All rights reserved. MammaPrint and Blueprint are registered
trademarks of Agendia, Inc.





Page load link

OUR COOKIE POLICY

We use cookies on our website to give you the most relevant experience by
remembering your preferences and repeat visits. By clicking “Accept”, you
consent to the use of ALL the cookies.


Do not sell my personal informationACCEPT
Privacy & Cookies Policy
Close

PRIVACY OVERVIEW

This website uses cookies to improve your experience while you navigate through
the website. Out of these cookies, the cookies that are categorized as necessary
are stored on your browser as they are essential for the working of basic
functionalities...
Necessary
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly.
This category only includes cookies that ensures basic functionalities and
security features of the website. These cookies do not store any personal
information.
Non-necessary
Non-necessary
Any cookies that may not be particularly necessary for the website to function
and is used specifically to collect user personal data via analytics, ads, other
embedded contents are termed as non-necessary cookies. It is mandatory to
procure user consent prior to running these cookies on your website.
SAVE & ACCEPT





X




X



X



X


X


X

CHRISTY GARCIA

VICE PRESIDENT, COMPLIANCE

Christy Garcia, Vice President, Compliance joined Agendia in February 2021.
Prior to Agendia, she served as chief privacy officer and director of compliance
for Myriad Genetics. She also held quality and compliance positions at Atricure,
Inc. and Ethicon Endo Surgery, Inc. Mrs. Garcia graduated from Northern Kentucky
University with an A.A. in Integrative Studies and a B.A. in Organizational
Leadership. She has compliance and privacy certifications in the US and from
Seton Hall. She is a member of the Health Care Compliance Association and
International Association of Privacy Professionals.

X



X

PROF. LAURA VAN ‘T VEER, PHD

CHIEF RESEARCH OFFICER (CRO) AND CO‑FOUNDER

Prof. Laura van ‘t Veer, PhD, is co‑founder of Agendia and serves as its Chief
Research Officer. As one of the world’s leading innovators in cancer
diagnostics, she is widely recognized as a pioneer in the field of personalized
medicine, also known as precision medicine. She has a 20-year track record in
molecular oncology research, which includes more than 230 scientific
publications and prestigious awards for her contributions to breast cancer care.

Dr. van ‘t Veer is best known for work stemming from a discovery she and her
team made at the Netherlands Cancer Institute (NKI). They established that a
specific DNA signature made up of 70 genes distinguished whether breast cancer
tumors had a low or high risk of recurrence. After patenting their innovation,
she and research partner René Bernards founded Agendia and launched the
MammaPrint test.

In 2010, Dr. van ‘t Veer was appointed Professor of Laboratory Medicine and
Director of Applied Genomics at the University of California San Francisco. She
is also the former head of the NKI’s DNA-diagnostic laboratory. She was awarded
a 2014 European Union Prize for Women Innovators that acknowledges the ways
MammaPrint has helped transform breast cancer care. In 2015, the European Patent
Office (EPO) recognized MammaPrint’s impact on breast cancer diagnostics by
honoring Dr. van ‘t Veer with a European Inventor Award.

X

ROOPOM BANERJEE

CHIEF STRATEGY OFFICER AND HEAD OF BUSINESS DEVELOPMENT

Roopom is a life science business leader with 20 years’ experience covering
strategy, financial advisory, operational and scientific roles. He has broad
experience with startups to global Fortune 500 companies advising on corporate
strategy, portfolio design, product development and commercialization,
financing, partnerships and acquisitions. Most recently, he was President and
CEO of RainDance Technologies (acquired by BioRad Labs) and led the company to
become a pioneer in Liquid Biopsy for detecting cancer from a blood test.

Previously, Roopom led teams at McKinsey, Leerink and Goldman Sachs where he
completed 80+ healthcare transactions raising over $10Bn in capital financings,
30+ IPOs, and 20+ M&A transactions. His earlier career spanned scientific cancer
research at the Dana Farber Cancer Institute and Human Genome Project.

A biochemist and economist by training, Roopom has a graduate degree from
Harvard and two undergrad degrees from MIT where he was elected a Howard Hughes
Medical Institute Scholar.

X

WENDY BLOSSER

CHIEF COMMERCIAL OFFICER (CMO)

Wendy joined Agendia in May 2019 and brings 20 years of success in launching,
relaunching and leading commercial organizations in diagnostic, surgical and
capital sales, with a focus in Oncology and Women’s Health. She also comes with
extensive experience in marketing, corporate advocacy and sales training.



Wendy’s career history includes working at Animated Dynamics, Strand
Diagnostics, Biodesix, Integrated Oncology, and Cytyc Corporation. Most
recently, Wendy served as CCO for Animated Dynamics, an imaging company that
delivers drug assessments in 3D living tissue samples. Prior to that, Wendy
served as CCO with Biodesix, where she relaunched VeriStrat and brought the
GeneStrat test to market, both of which resulted in continuous record growth.

Previous to Biodesix, Wendy served as VP of Sales with Integrated Oncology, and
her responsibilities included successfully integrating US Labs and Genzyme
Genetics under one umbrella.

Wendy’s tenure with Precision Therapeutics included national sales roles and a
relaunch of the company’s ChemoFx product, which helped lead to large expansion
of the company’s revenue growth. Wendy also has start up experience with
Vermillion and Cytyc Corporation (now Hologic).

Wendy is based out of Ohio and holds a Master of Science from the University of
West Virginia and a Bachelor of Science from Marietta College.

X

BASTIAAN VAN DER BAAN

CHIEF CLINICAL AND BUSINESS DEVELOPMENT OFFICER

Bas van der Baan is Chief Clinical and Business Development Officer at Agendia
and joined the Company shortly after its founding in 2003. Bas holds a degree in
molecular sciences and has over 15 years of healthcare experience in commercial
roles, and has held positions at Unilever and other biotechnology start-ups.

X

PROF. DR. RENÉ BERNARDS, PHD

CHIEF SCIENTIFIC OFFICER (CSO) AND CO‑FOUNDER

Prof. Dr. René Bernards is Chief Scientific Officer of Agendia and also a
co‑founder of the Company. René has a 30-year track record in oncology research,
with more than 150 published papers in peer-reviewed journals. He is the Head of
Division of Molecular Carcinogenesis of the Netherlands Cancer Institute,
professor of Molecular Carcinogenesis at Utrecht University and member of the
Royal Netherlands Academy of Arts and Sciences (KNAW). In addition René is a
member of the Scientific Advisory Board of Gilde Healthcare fund.

X

WILLIAM AUDEH, MD, MS

CHIEF MEDICAL OFFICER (CMO)

Dr. William Audeh is a medical oncologist specializing in breast cancer, with
nearly 30 years of experience as a clinician and clinical researcher at the
Cedars-Sinai Cancer Center in Los Angeles, where he continues to be a member of
the Medical Staff. Prior to joining Agendia, and in addition to his clinical
practice, he served as the former Director of the Cedars-Sinai Cancer Center and
Medical Director of the Wasserman Breast Cancer Risk Reduction Program. Dr.
Audeh also served as Director of the Medical Oncology Training Program for
Breast Surgery and Surgical Oncology Fellowships at Cedars-Sinai, and is
Associate Clinical Professor of Medicine at the UCLA David Geffen School of
Medicine. Dr. Audeh has been Principal Investigator on a wide variety of
national and international clinical and translational trials, and has authored
numerous publications in the field of breast cancer, cancer genomics, and
targeted cancer therapy.

Dr. Audeh received his medical degree from the University of Iowa and an M.S.
Degree in Genetics from the University of Minnesota. He went on to complete his
residency in Internal Medicine as well as a fellowship in Medical Oncology at
Stanford University Medical Center. He is board certified on internal medicine
and medical oncology, and is a member of the American Society of Clinical
Oncology and American Association of Cancer Research.

X

BRIAN DOW

CHIEF FINANCIAL OFFICER (CFO)

Brian Dow joined Agendia in June 2020 as Chief Financial Officer with more than
25 years of financial, accounting and operations experience with a focus on
public and emerging life sciences companies. Most recently, Brian served as
Chief Financial Officer & Senior Vice President, Finance and Administration of
Pulse Biosciences, a medical technology company developing a novel energy-based
tissue treatment platform. Prior to that role, he was the Vice President and
Principal Accounting Officer of Pacific Biosciences of California, a leading
provider of next generation genetic sequencing instruments. In addition, Brian
held a series of financial officer positions, more recently serving as the Chief
Financial Officer with Northstar Neuroscience, Inc., a development stage medical
device company. Brian began his career as a manager with Ernst and Young after
earning his Bachelor of Science degree in Management from the Georgia Institute
of Technology. Brian is also recognized as a licensed Certified Public
Accountant by the Washington State Board of Accountancy.

X

MARK R. STRALEY

CHIEF EXECUTIVE OFFICER (CEO)

Mr. Mark R. Straley joined Agendia Inc. in August 2015 as the company’s CEO,
bringing more than 25 years of international experience developing and
commercializing clinical diagnostics and laboratory services. Most recently he
served as President, Anatomical Pathology of Thermo Fisher Scientific of
Waltham, Massachusetts. Prior to this position he was President and CEO of
Metamark Genetics of Cambridge, Massachusetts, a biotech company focusing on the
development of prognostic and predictive diagnostic tests for personalized
treatment of cancer patients. From 2005 to 2010, Mark held positions at Ortho
Clinical Diagnostics, a J&J company, first as Worldwide Vice President of
Marketing and then as Worldwide President. Prior to his assignment with J&J,
Mark worked for such brand name companies as Bayer Healthcare and Abbott
Laboratories where he held positions of increasing responsibility. Mark earned a
Bachelor of Science degree in Marketing from Miami University.





X


NOTICE TO AGENCIES

Agendia does not accept unsolicited resumes from any third-party recruiters,
agencies or individuals. All third party recruiters, agencies or individuals
seeking to work with Agendia must first contact Human Resources
at jobs@agendia.com. Only approved staffing vendors will be allowed to provide
services to Agendia. Unsolicited resumes submitted directly to hiring managers,
employees or representatives will be deemed the property of Agendia to follow up
with as it sees applicable, and no fee will be paid in the event a candidate is
hired as a result of the referral or by other means. Submission of unsolicited
resumes does not create any implied obligation on the part of Agendia.

[THJM_JOBS]

X

KURT BECKER

CHIEF OPERATIONS OFFICER (COO)

Kurt joined Agendia in March of 2012 and has more than fifteen years of
experience in financial management and analytics in healthcare, banking and
aerospace industries. His previous public company experience has been at
Alphatec Spine, Wells Fargo and UTC Aerospace. Kurt holds a Master’s of Science
in Business Administration degree from San Diego State University with a focus
on Finance and a Bachelor of Science degree in Finance from the University of
Wisconsin-Milwaukee.

X


AGENDIA CMS COMPLIANCE

Agendia, Inc. is committed to providing quality testing for patients and their
treating physicians by offering timely results, reliable customer service, and
adhering to responsible billing practices. As a part of Agendia’s regulatory
policy, we follow all Federal & State requirements, based on applicable rules
and regulations as it relates to Clinical Laboratory services.


WHAT IS THE 14-DAY RULE?

The “14 Day Rule” is a regulation set forth by the Centers for Medicare &
Medicaid Services (CMS) that generally requires laboratories, including Agendia,
to bill a hospital or hospital-owned facility for certain clinical and pathology
laboratory services and the technical component of pathology services provided
to Medicare patients when services are ordered less than 14 days after an
inpatient discharge.


HOW DO WE DETERMINE THE DATE OF SERVICE?

In general, the date of service (DOS) for clinical diagnostic laboratory tests
is the date of specimen collection unless the physician orders the test at least
14 days following the patient’s discharge from the hospital. In the latter
situation, the DOS is the date the test is performed, instead of the date of
specimen collection.


WHO IS IMPACTED BY THE 14-DAY RULE?

Hospitals and hospital-owned facilities where the patient’s specimen was
collected for a hospital inpatient encounter.


IS THERE AN EXCEPTION TO THE DATE OF SERVICE (DOS) POLICY?

 * The test is performed following a hospital outpatient’s discharge from the
   hospital outpatient department:
 * The specimen was collected from a hospital outpatient during an encounter (as
   both are defined 42 CFR 410.2);
 * It was medically appropriate to have collected the sample from the hospital
   outpatient during the hospital outpatient encounter;
 * The results of the test do not guide treatment provided during the hospital
   outpatient encounter; and
 * The test was reasonable and medically necessary for the treatment of an
   illness

Below is an outline of the scenarios under which the Medicare date of service
rules will apply to Agendia’s tests. The decision to submit an order for testing
should be guided by the clinical judgment of the ordering physician and should
not be based on the application of any billing rules.

Status at Specimen Collection

Outpatient
Nonpatient
Inpatient; ordered >14 days after date of discharge
Inpatient; ordered >14 days after date of discharge

Medicare Billing
Agendia, Inc. bills Medicare

Agendia, Inc. bills Hospital

X
Go to Top